Document is current
Any future updates will be listed below
-
Authors
Brockman, Deanna G.
Petronio, Lia
Dron, Jacqueline S.
Kwon, Bum Chul
Vosburg, Trish
Nip, Lisa
Tang, Andrew
O’Reilly, Mary
Lennon, Niall
Wong, Bang
Ng, Kenney
Huang, Katherine H.
Fahed, Akl C.
Khera, Amit V. https://orcid.org/0000-0001-6535-5839
-
Funding
Funding for this research was provided by:
national human genome research institute (1K08HG010155, 1U01HG011719)
ibm research
broad institute (Broad SPARC, Merkin Institute Fellowship)
massachusetts general hospital (Hassenfeld Scholar Award)
- License Information
-
More Information
Article History
Received: 25 July 2021
Accepted: 12 August 2021
First Online: 1 October 2021
Declarations
:
: All study participants provided verbal consent. This study, including use of verbal consent, was approved as minimal risk, and given exempt status by the Massachusetts General Brigham Institutional Review Board (2020P003088). Given the COVID-19 pandemic, and challenges surrounding documentation of written consent for virtual participation in studies, verbal consent was approved. Verbal consent was documented by D.G.B. in a spreadsheet accessible only to research study staff.
: Not applicable.
: BCK and KN are employees of IBM Research. ACF is a consultant and holds equity in Goodpath. AVK has served as a scientific advisor to Sanofi, Amgen, Maze Therapeutics, Navitor Pharmaceuticals, Sarepta Therapeutics, Verve Therapeutics, Veritas International, Color Health, Third Rock Ventures, and Columbia University (NIH); received speaking fees from Illumina, MedGenome, Amgen, and the Novartis Institute for Biomedical Research; and received a sponsored research agreement from the Novartis Institute for Biomedical Research.
